Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic... by Hsiang-Ying Wu (22212274)

“…This meta-analysis found that HR(+)/HER2(−) metastatic breast cancer treated with CDK4/6 inhibitors plus endocrine therapy can significantly improve progression-free survival(PFS) (HR: 0.55; <i>p</i> < 0.001), overall survival (OS) (HR: 0.79; <i>p</i> < 0.001), objective response rate (RR = 1.50; <i>p</i> < 0.001), clinical benefit rate (RR = 1.18; <i>p</i> < 0.001) and decrease progressive disease rate (RR = 0.49; <i>p</i> < 0.001). …”

Image_2_Abnormal outer and inner retina in a mouse model of Huntington’s disease with age.JPEG by Dashuang Yang (19956078)

“…<p>Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction and cognitive decline. …”

Image_1_Abnormal outer and inner retina in a mouse model of Huntington’s disease with age.JPEG by Dashuang Yang (19956078)

“…<p>Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction and cognitive decline. …”

Image_3_Abnormal outer and inner retina in a mouse model of Huntington’s disease with age.JPEG by Dashuang Yang (19956078)

“…<p>Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction and cognitive decline. …”

Table_1_Abnormal outer and inner retina in a mouse model of Huntington’s disease with age.DOCX by Dashuang Yang (19956078)

“…<p>Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction and cognitive decline. …”

Data Sheet 1_Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-in... by Zhixue Fu (7540256)

“…Overall survival (OS), progression-free survival (PFS), recurrence pattern, and safety were evaluated.…”

Image 4_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Image 2_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Opposing mechanisms by which miRNAs mediate distinct Nrf1 and Nrf2 regulation of epithelial–mesenchymal transition in hepatocellular carcinoma by Juan Chen (61123)

“…The <i>Nrf1α</i>^{<i>–/–</i>}-leading EMT results from a significant decrease in the epithelial CDH1 expression, plus another increased expression of the mesenchymal CDH2. …”

Table 1_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Image 3_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Image 1_Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinem... by Shida Pan (12696593)

“…Patients with a decrease in TBIL levels within one week had significantly prolonged median OS (not reached vs 3.3months, P =0.013) and median PFS (7.03 months vs 2.77 months, P =0.010).…”

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... by Xinhang Gu (22686224)

“…Propensity score matching (PSM) was implemented to decrease bias. The primary endpoint was progression-free survival (PFS). …”

Upper extremity orthopedic softball injuries presenting to the emergency department: epidemiology across the lifespan by David F. Painter (12884672)

“…The average incidence rate of UE injuries from 2012–2021 was 187.9 per 100,000 persons, with a significant decrease in injury incidence across the timespan (<i>p</i> < .001). …”

List of DEGs from neuronal cell analysis. by Sara Cuvertino (18892069)

“…In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. Our analysis reveals significant enrichment of differentially downregulated genes in areas containing putative enhancer regions with H3K4me1 loss. …”

List of HipSci cell lines used in the study. by Sara Cuvertino (18892069)

“…In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. Our analysis reveals significant enrichment of differentially downregulated genes in areas containing putative enhancer regions with H3K4me1 loss. …”

List of DEGs from iPSC analysis. by Sara Cuvertino (18892069)

“…In contrast with the epigenomic changes, the number of DEGs decrease as differentiation progresses. Our analysis reveals significant enrichment of differentially downregulated genes in areas containing putative enhancer regions with H3K4me1 loss. …”

ALKBH5 induces macrophage activation to promote renal fibrosis via Retnla by Long Zheng (694761)

“…Macrophage-specific ALKBH5 knockout could significantly alleviate renal fibrosis in UUO mice and decrease the infiltration of macrophages in the kidneys. …”

Supplementary file 1_Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis.docx by Yajie Yin (10115902)

“…Improved fibrosis: significant reduction in pulmonary fibrosis score (SMD = −2.30, 95% CI [−2.80, −1.79], p < 0.00001, I² = 76%) and decreased Hyp content (SMD = −2.16, 95% CI [−2.69, −1.63], p < 0.00001, I² = 85%); 2. …”

Data Sheet 1_Antiretroviral therapy initiated during acute infection in women with HIV-1 clade C reduces anti-Tat antibody production and lowers CD8+ T cell activation.pdf by Thandeka I. Kubheka (21562460)

“…</p>Results<p>The data showed that anti-Tat IgG and IgM titres had decreased significantly after 12 months of treatment (p=0.0001) with no correlation between anti-Tat IgA, IgG or IgM and CD4+ T-cell counts (r= -0.09 to 0.2, p>0.05). …”